CELC Live signals | Maximize Profits with Getagraph.com

BUY 105425 min ago

@ $15.21

Issued: 13 Feb 2024 @ 09:42

Return: 4.14%

Previous signal: Feb 9 - 09:30

Previous signal: Sell

Return: 3.75 %

Live Chart Being Loaded With Signals

Commentary (26 Apr 2024 @ 15:47):

Celcuity Inc., a clinical stage biotechnology company, focuses on the development of molecularly targeted therapies for cancer patients in the United States...

Stats
Today's Volume	628 404
Average Volume	218 991
Market Cap	482.38M
EPS	$0 ( 2024-03-27 )
Next earnings date	( $0 ) 2024-05-13
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-5.89
ATR14	$0.0330 (0.21%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-08	Buller Richard E	Buy	19 558	Stock Option (right to buy)
2024-04-08	Buller Richard E	Buy	12 654	Stock Option (right to buy)
2024-04-08	Buller Richard E	Buy	4 555	Stock Option (right to buy)
2024-04-08	Buller Richard E	Buy	2 310	Stock Option (right to buy)
2024-04-08	Buller Richard E	Sell	19 558	Stock Option (right to buy)

INSIDER POWER
9.00
Last 100 transactions
Buy: 4 086 807 \| Sell: 2 961 758

Volume Correlation

Long: -0.17 (neutral)

Short: 0.07 (neutral)

Signal:(59.48) Neutral

Celcuity Inc Correlation

10 Most Positive Correlations
ALKT	0.868
NNBR	0.864
DDI	0.861
AVDX	0.859
SPLK	0.856
TTSH	0.856
FCBC	0.852
BFI	0.85
ESQ	0.848
ADV	0.843

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Celcuity Inc Correlation - Currency/Commodity

0.05
( neutral )

0.42
( neutral )

0.00
( neutral )

-0.19
( neutral )

-0.32
( neutral )

-0.88
( strong negative )

Celcuity Inc Financials

Annual	2023
Revenue:	$0
Gross Profit:	$-142 772 (0.00 %)
EPS:	$-2.69

FY	2023
Revenue:	$0
Gross Profit:	$-142 772 (0.00 %)
EPS:	$-2.69

FY	2022
Revenue:	$0
Gross Profit:	$-210 918 (0.00 %)
EPS:	$-2.68

FY	2021
Revenue:	$0.00
Gross Profit:	$0.00 (0.00 %)
EPS:	$-2.88

Financial Reports:

No articles found.

Celcuity Inc

Celcuity Inc., a clinical stage biotechnology company, focuses on the development of molecularly targeted therapies for cancer patients in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, and advanced or metastatic breast cancer. The company is also developing CELsignia MP test, a qualitative laboratory developed test that measures HER2, c-Met, and PI3K signaling activity in breast and ovarian tumor cells. It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. Celcuity Inc. was founded in 2011 and is headquartered in Minneapolis, Minnesota.